Opportunity Information: Apply for RFA HL 13 014
Apply for RFA HL 13 014
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition Pregnancy as a Window to Future Cardiovascular Health Adverse Pregnancy Outcomes as Predictors of Increased Risk Factors for Cardiovascular Disease (U10)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233 National Center on Sleep Disorders Research 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Oct 30, 2012 and posted on Aug 10, 2012.
- Applicants must submit their applications by Oct 31, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Only those institutions in the NuMoM2b parent study funded by the Eunice Kennedy Shriver NICHD at the date of issuance of this FOA are eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Limited Competition Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy Outcomes as Predictors of Increased Risk Factors for Cardiovascular Disease (U10)" (Funding Opportunity Number RFA-HL-13-014) is a National Institutes of Health (NIH) funding announcement that supports a targeted follow-up study of women who previously participated in the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (NuMoM2b). The central idea behind the opportunity is that pregnancy can reveal early warning signs about a womans future cardiovascular health, especially when complications such as preeclampsia or other adverse pregnancy outcomes (APOs) occur. This FOA aims to leverage the existing NuMoM2b cohort to determine how these pregnancy complications relate to measurable cardiovascular risk profiles later, focusing specifically on assessments at roughly two years after delivery.
This is a limited competition announcement, meaning it is not broadly open to all institutions. Eligibility is restricted to institutions already funded as part of the NuMoM2b parent study by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) as of the date the FOA was issued. In practical terms, only the established NuMoM2b clinical research sites and the NuMoM2b Data Coordinating and Analysis Center (DCAC) are permitted to apply. The structure reflects the intent to build directly on an existing, well-characterized cohort with established study infrastructure rather than creating a new cohort from scratch.
The award mechanism is a Cooperative Agreement (U10), which typically indicates substantial scientific or programmatic involvement by NIH staff during the project. Rather than being a purely investigator-driven grant with minimal agency interaction, a U10 generally involves coordinated activities across multiple sites, common protocols, centralized oversight, and close collaboration between awardees and NIH program leadership. The activity category is Health, and the announcement is associated with multiple CFDA numbers, including 93.233 (National Center on Sleep Disorders Research) and several NHLBI-related research categories (93.837 Cardiovascular Diseases Research, 93.838 Lung Diseases Research, 93.839 Blood Diseases and Resources Research). No cost sharing or matching is required.
Scientifically, the FOA is focused on prospective follow-up of the NuMoM2b cohort to evaluate cardiovascular risk after pregnancy, with particular emphasis on women who experienced preeclampsia and other adverse pregnancy outcomes. The target follow-up window is approximately two years postpartum, a time point that is early enough to identify emerging risk factors while still being close enough to pregnancy to plausibly connect pregnancy-related physiology and complications with subsequent cardiovascular changes. The goal is not simply to document whether cardiovascular disease eventually occurs decades later, but to characterize the cardiovascular risk profile in the nearer term, which can include established risk factors and subclinical indicators that predict later disease.
From a public health and clinical perspective, this opportunity is grounded in the growing recognition that adverse pregnancy outcomes can function as an early stress test for the cardiovascular system. Conditions like preeclampsia are associated in the broader scientific literature with higher future risk of hypertension, ischemic heart disease, stroke, and other cardiovascular conditions. By funding a coordinated follow-up of a rigorously studied cohort of first-time mothers, the NIH is seeking clearer evidence on which postpartum characteristics, biomarkers, physiologic measures, and clinical factors distinguish women at elevated cardiovascular risk after an APO. This kind of work can inform earlier screening, prevention strategies, and potential interventions targeted to women who may appear healthy before pregnancy but demonstrate risk through pregnancy complications.
Administratively, the FOA was posted on Aug 10, 2012, with key dates including an original closing date of Oct 30, 2012, and a current closing date of Oct 31, 2012. The opportunity was archived on Nov 30, 2012. The official full announcement and details were made available through the NIH grants guide website link provided in the source data. For technical access issues, the contact route referenced is the NIH Office of Extramural Research (OER) Webmaster email.
Overall, this grant opportunity is a narrowly targeted NIH initiative designed to extend the value of the NuMoM2b investment by following participants beyond pregnancy and into the postpartum period, using a collaborative, multi-site cooperative agreement model. Its main purpose is to clarify how preeclampsia and other adverse pregnancy outcomes are linked to an unfavorable cardiovascular risk profile by about two years postpartum, with the broader intent of improving long-term cardiovascular health prediction and prevention for women based on pregnancy history.
FAQs: Limited Competition Pregnancy as a Window to Future Cardiovascular Health (U10) - RFA-HL-13-014
What is the official title and funding opportunity number for this grant?
The opportunity is titled "Limited Competition Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy Outcomes as Predictors of Increased Risk Factors for Cardiovascular Disease (U10)" and the Funding Opportunity Number (FOA) is RFA-HL-13-014.
Which agency is offering this funding opportunity?
This is a National Institutes of Health (NIH) funding announcement.
What is the main purpose of this FOA?
The FOA supports a targeted follow-up study of women who previously participated in the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (NuMoM2b). The goal is to evaluate how adverse pregnancy outcomes (APOs), including preeclampsia, relate to cardiovascular risk profiles later, with assessments occurring at roughly two years after delivery.
What is the central scientific idea behind the study?
The FOA is based on the concept that pregnancy can act as an early "window" into a woman's future cardiovascular health. Complications during pregnancy, such as preeclampsia and other APOs, may reveal early warning signs of elevated cardiovascular risk.
Is this opportunity open to all institutions?
No. This is a limited competition announcement and is not broadly open to all institutions.
Who is eligible to apply?
Eligibility is restricted to institutions already funded as part of the NuMoM2b parent study by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) as of the date the FOA was issued. Practically, only the established NuMoM2b clinical research sites and the NuMoM2b Data Coordinating and Analysis Center (DCAC) are permitted to apply.
Why is the competition limited?
The FOA is designed to build directly on the existing, well-characterized NuMoM2b cohort and its established infrastructure. The intent is to leverage prior investment and standardized data and procedures rather than create a new cohort from scratch.
What type of award mechanism is used?
The award mechanism is a Cooperative Agreement (U10).
What does a U10 Cooperative Agreement typically imply for project operations?
A U10 generally indicates substantial scientific or programmatic involvement by NIH staff. It typically involves coordinated activities across multiple sites, common protocols, centralized oversight, and close collaboration between awardees and NIH program leadership.
What is the activity category for this opportunity?
The activity category is Health.
Does this FOA require cost sharing or matching funds?
No. The FOA states that no cost sharing or matching is required.
What population is being followed in this study?
The follow-up focuses on women who previously participated in the NuMoM2b study (a cohort of first-time mothers).
What kinds of pregnancy events are of particular interest?
The FOA places particular emphasis on preeclampsia and other adverse pregnancy outcomes (APOs) as predictors of increased cardiovascular risk factors.
What is the planned follow-up timing after pregnancy?
The target follow-up window is approximately two years postpartum (about two years after delivery).
Why focus on approximately two years postpartum?
This time point is described as early enough to identify emerging cardiovascular risk factors while still being close enough to pregnancy to plausibly connect pregnancy-related physiology and complications with subsequent cardiovascular changes.
Is the FOA focused on long-term cardiovascular events decades later?
No. The emphasis is not simply on documenting whether cardiovascular disease occurs decades later, but on characterizing cardiovascular risk profiles in the nearer term, including established risk factors and subclinical indicators that predict later disease.
What kinds of outcomes or measures does the FOA aim to characterize?
Based on the FOA description, the study aims to identify postpartum characteristics that distinguish women at elevated cardiovascular risk after an APO. This can include cardiovascular risk factors and subclinical indicators, and may involve biomarkers, physiologic measures, and clinical factors.
What is the public health or clinical rationale for this work?
The FOA is grounded in growing recognition that adverse pregnancy outcomes can function as an early stress test for the cardiovascular system. The broader intent is to improve prediction and prevention of long-term cardiovascular disease in women by using pregnancy history, particularly APOs, as an early risk signal.
Which cardiovascular conditions are mentioned as being associated with preeclampsia in the broader literature?
The FOA notes that conditions like preeclampsia are associated in the broader scientific literature with higher future risk of hypertension, ischemic heart disease, stroke, and other cardiovascular conditions.
What specific NIH institute is referenced with respect to eligibility for the parent study?
Eligibility is tied to institutions funded as part of the NuMoM2b parent study by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) as of the date the FOA was issued.
What are the CFDA numbers associated with this announcement?
The opportunity is associated with multiple CFDA numbers, including 93.233 (National Center on Sleep Disorders Research) and NHLBI-related research categories: 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), and 93.839 (Blood Diseases and Resources Research).
When was the FOA posted?
The FOA was posted on Aug 10, 2012.
What were the closing dates for applications?
The key dates listed include an original closing date of Oct 30, 2012, and a current closing date of Oct 31, 2012.
Is the opportunity still active?
No. The opportunity was archived on Nov 30, 2012.
Where were the official full announcement and details provided?
The full announcement and details were made available through the NIH grants guide website link referenced in the source data.
Who is the contact for technical access issues?
For technical access issues, the contact route referenced is the NIH Office of Extramural Research (OER) Webmaster email.
What is the overall design approach emphasized by the FOA?
The FOA emphasizes a coordinated, multi-site follow-up effort that leverages the existing NuMoM2b cohort and infrastructure, implemented through a cooperative agreement model with close collaboration and centralized oversight.
Browse more opportunities from the same category: Health
Next opportunity: FY12 Earthquake and Building Science Program Implementation
Previous opportunity: National Center for Mobility Management
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 13 014
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 13 014) also looked into and applied for these:
| Funding Opportunity |
|---|
| Rural Health Network Development Planning Program Apply for HRSA 13 153 Funding Number: HRSA 13 153 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Molecular Mechanisms of Circadian Clocks in Aging Tissues (R01) Apply for RFA AG 13 007 Funding Number: RFA AG 13 007 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Secondary Analyses of CALERIE Data Set and Stored Biospecimens to Address Research Questions Related to Effects of Caloric Restriction in Humans and Adherence to Caloric Restriction Interventions (R01) Apply for RFA AG 13 008 Funding Number: RFA AG 13 008 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| National Indian Health Outreach and Education Apply for HHS 2012 IHS NIHOE 0001 Funding Number: HHS 2012 IHS NIHOE 0001 Agency: Indian Health Service Category: Health Funding Amount: $966,000 |
| National Indian Health Outreach and Education Apply for HHS 2012 IHS NIHOE 0003 Funding Number: HHS 2012 IHS NIHOE 0003 Agency: Indian Health Service Category: Health Funding Amount: $600,000 |
| Human Heredity and Health in Africa (H3Africa) H3Africa Biorepository Grants. (UH2/UH3) Apply for RFA RM 12 008 Funding Number: RFA RM 12 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Healthy Tomorrows Partnership for Children Program (HTPCP) Apply for HRSA 13 176 Funding Number: HRSA 13 176 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Tobacco Control Regulatory Research R21 Apply for PAR 12 266 Funding Number: PAR 12 266 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Tobacco Control Regulatory Research R01 Apply for PAR 12 267 Funding Number: PAR 12 267 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tobacco Control Regulatory Research R03 Apply for PAR 12 268 Funding Number: PAR 12 268 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| ACA SHIP and ADRC Options Counseling for Medicare Medicaid Individuals in States with Approved Financial Alignment Model Apply for CMS 1N1 12 001 Funding Number: CMS 1N1 12 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $1,000,000 |
| Potential Effects of Metformin on Aging and Age Related Conditions Small Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01) Apply for PA 12 271 Funding Number: PA 12 271 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Institute on Aging Revision Requests for Active Alzheimers Disease Core Centers (P30) Apply for PAR 12 272 Funding Number: PAR 12 272 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement for the Development and Support of Core Public Health Functions Related to Injury Prevention and Control Apply for CDC RFA CE08 8010502SUPP12 Funding Number: CDC RFA CE08 8010502SUPP12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $16,400 |
| NIMH Research Education Mentoring Programs for HIV/AIDS Researchers (R25) Apply for PAR 12 273 Funding Number: PAR 12 273 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Secondary Analyses and Archiving of Social and Behavioral Datasets in Aging (R03) Apply for RFA AG 13 009 Funding Number: RFA AG 13 009 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Bridges to the Doctorate Program (R25) Apply for PAR 12 276 Funding Number: PAR 12 276 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Bridges to the Baccalaureate Program (R25) Apply for PAR 12 277 Funding Number: PAR 12 277 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| DELTA FOCUS (Domestic Violence Prevention Enhancement and Leadership Through Alliances, Focusing on Outcomes for Communities United with States) Apply for CDC RFA CE13 1302 Funding Number: CDC RFA CE13 1302 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $410,000 |
| AHRQ Patient Centered Outcomes Research (PCOR) Pathway to Independence Award (K99/R00) Apply for RFA HS 13 002 Funding Number: RFA HS 13 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 13 014", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.